Author details

Full Name

Jean-Philippe Theurillat

Affiliation

ORCID

Career Start Year

1999

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37295433	Minor intron splicing is critical for survival of lethal prostate cancer.	Mol Cell	2023
34974131	SPOP-mutant prostate cancer: Translating fundamental biology into patient care.	Cancer Letters	2022
34616044	Metabolic modulation of tumours with engineered bacteria for immunotherapy.	Nature	2021
33531470	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.	Nat Commun	2021
34031014	Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us.	Trends Cancer	2021
33602919	Patient-derived xenografts and organoids model therapy response in prostate cancer.	Nat Commun	2021
33500545	Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer.	Communications Biology	2021
33420371	Loss and revival of androgen receptor signaling in advanced prostate cancer.	Oncogene	2021
34857732	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression.	Nat Commun	2021
34618582	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.	Science	2021
32331546	Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology.	Chimia	2020
32323921	STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancer.	Mol Syst Biol	2020
32024754	TIP5 primes prostate luminal cells for the oncogenic transformation mediated by <i>PTEN</i>-loss.	Proc Natl Acad Sci U S A	2020
32250342	CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.	J Clin Invest	2020
32109420	De Novo Variants in SPOP Cause Two Clinically Distinct Neurodevelopmental Disorders.	Am J Hum Genet	2020
28805821	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.	Nat Med	2017
27610751	Targeting transcriptional co-activators in advanced prostate cancer.	Cell Cycle	2016
27238081	TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.	Cancer Cell	2016
26956048	Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas.	Oncotarget	2016
27411590	Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma.	Cancer Cell	2016
24737027	A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein.	Mol Cancer Ther	2014
25278611	Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.	Science	2014
23288408	A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.	Cancer Discov	2013
23622249	Punctuated evolution of prostate cancer genomes.	Cell	2013
22817889	A landscape of driver mutations in melanoma.	Cell	2012
22610119	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.	Nat Genet	2012
20958924	Old proteins - new locations: myoglobin, haemoglobin, neuroglobin and cytoglobin in solid tumours and cancer cells.	Acta Physiologica	2011
21397856	URI is an oncogene amplified in ovarian cancer cells and is required for their survival.	Cancer Cell	2011
20495541	Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer.	Mod Pathol	2010
20531416	Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype.	Br J Cancer	2010
20103684	IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity.	Clin Cancer Res	2010
19250911	A role for NBR1 in autophagosomal degradation of ubiquitinated substrates.	Mol Cell	2009
18041742	Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts.	Int J Cancer	2008
17294444	NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration.	Int J Cancer	2007
17410359	NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy.	Cancer Immunol Immunother	2007
16675566	Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases.	Clin Cancer Res	2006
12812318	Morphologic changes and altered gene expression in an epithelioid hemangioendothelioma during a ten-year course of disease.	Pathology Research and Practice	2003
10027415	Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice.	Am J Pathol	1999